Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/58—[b]- or [c]-condensed
  • C07D209/72—4,7-Endo-alkylene-iso-indoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems

Definitions

• This invention relates to novel compounds having utility in the treatment of central nervous systems disorders such as anxiety, psychosis, depression and sexual dysfunction.
• Recent research has provided a growing body of literature which attributes the activity of some of the newer classes of CNS agents to their selective activation of the serotonin receptor subtype designated the 5-HTIA receptor.
• buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ] butyl ]-8-azaspiro[4.5 ]decane-7,9-dione
• TVX Q 7821 (2-[4-[4-(2-pyrimidinylM-piperazinyl ] butyl ]-l,2-benziso- thiazol-3-(2H)one 1,1-dioxide hydrochloride).
• buspirone-like compounds activating the 5-HTIA receptor site are useful as anxiolytics/antipsyehoties, antidepressants and in the treatment of sexual dysfunction.
• the compounds of the invention are characterized by the formula
• X is lower alkylene, vinylene or O
• Y is lower alkylene or vinylene; n is 2 - 4; the dotted line represents an optional double bond; m is 1 - 3; A is phenyl, benzoyl, pyridinyl, quinolinyl or quinoxalinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl; or when m is >1, A represents the grouping
• B is phenyl, pyrimidinyl, pyridinyl or pyrazinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo f cyano, nitro or trifluoromethyl, with the proviso that where R
• A is other than unsubstituted or substituted benzoyl or pyridinyl; and the pharmacologically acceptable salts thereof.
• lower alkyl refers to moieties having 1 - 6 carbon atoms in the carbon chain.
• lower alkylene refers to moieties having 1 - 4 carbon atoms in the carbon chain.
• lower alkoxy refers to moieties having 1 - 6 carbon atoms.
• halo refers to fluoro, chloro and bromo.
• the compounds of the invention can form pharmacologically acceptable salts from pharmacologically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, sulfonie, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, itaconic and benzenesulfonic.
• pharmacologically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, sulfonie, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, ita
• This intermediate product can then be reacted with, for example, an appropriately substituted 4-piperazinylalkylhalide to yield the desired final product: - 4 -
• polycyclie amine intermediate can be reacted with a suitable dihalo lower alkane, followed by reaction with a suitable A-substi- tuent starting material:
• B, A and m are as defined hereinbefore and hal is a halo atom, such as chloro or bromo.
• hal is a halo atom, such as chloro or bromo.
• compounds of the invention or the pharmacologically acceptable salts thereof can be prepared by subjecting a cyclic amine having the formula
• maleimide can first be reacted with a dihalo lower alkane followed by reaction with an appropriate A substituent-containing starting material to yield the following intermediate:
• the saturated analogs of the compounds discussed in all of the previous preparative schemes can be prepared by hydrogenating the intermediates or the final products using hydrogen and Pd/C as a catalyst.
• the compounds of the invention may exist either in the form of the free base or the pharmacologically acceptable salts. Methods for converting one such form to another will be obvious to one skilled in the chemical arts.
• the compounds of the invention display a pharmacological profile like that of the compound buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ]- butyl ]-8-azaspiro[4.5 ]decane-7,9-dione).
• buspirone 8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ]- butyl ]-8-azaspiro[4.5 ]decane-7,9-dione.
• the latter compound has demonstrated preclinical activity in antipsychotic paradigms and has also displayed a unique clinical anxioselective profile, whereby its efficacy in the treatment of anxiety neuroses is comparable to the benzodiazepine diazepam but without the benzodiazepine-related side effects.
• the clinically effective anxiolytic doses of the benzodiazepines produce such undesirable side effects as ataxia, muscle relaxation and sedation.
• the compounds of the invention in a manner similar to buspirone, display preelinical antipsychotic activity with minimal or no side effects. Moreover, based on their buspirone- like profile, the compounds of the invention can be considered of clinical value in treating anxiety neuroses, depression as well as sexual dysfunction.
• the effective dosage of the substances active for such treatment will vary according to the particular compound being employed, the severity and nature of condition being treated. Therapy should be initiated at lower doses (in mg/kg/day), the dosage thereafter being increased, if necessary, to produce the desired effect.
• the compounds of the invention are most desirably administered at a concentration that will generally afford effective results without causing any harmful or deleterious effects.
• the compounds of the invention can be formulated into oral dosage forms such as tablets, capsules and the like.
• the compounds can be administered alone- or by combining them with conventional carriers, such as magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium car boxy methyleellulose, low melting wax, cocoa butter and the like. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, tablet-disintegrating agents and the like may be employed.
• the compounds may be encapsulated with or without other carriers. In all cases, the proportion of active ingrdients in said compositions both solid and liquid will be at least to impart the desired activity thereto on oral administration.
• the compounds may also be injected parenterally in which case they are used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
• a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
• the activity profile of the compounds of the invention and their substantial lack of extrapyramidal side effects may be demonstrated by standard pharmacological procedures, which are described more fully in the examples given hereafter.
• Example 1 shows the preparation and pharmacological testing of compounds within the invention.
• the methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
• the title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt, m.p. 173-174°C (2 g, 51% yield).
• the methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
• the title compound is separated by preparative HPLC using methanol as the an eluent and is converted to the dihydrochloride salt, m.p. 149-150°C (2.5 g, 54.4% yield).
• reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride.
• the methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
• the ex vivo inhibition of 5-HT ⁇ serotonin receptor binding assay is used to determine whether the test compounds can cross the blood-brain barrier and affect the receptor in question and to give an indication of buspirone-like activity.
• the assay is carried out as follows:
• rats Several groups of rats (4 - 6 rats/group) are injected with test compound or the appropriate vehicle. Thirty minutes later, unless otherwise noted, rats are decapitated and their brains removed. Various brain regions are dissected and rapidly frozen and maintained at -70° C until used.
• the homogenate is then centrifuged at 20,000 rpm (RC5-B; 40,000 g) and the supernatant discarded.
• the pellet is resuspended in 40 vols of the same buffer and incubated at 37° C for 10 minutes to aid in the removal of endogenous seroton
• the homogenate (50 ⁇ l; 0.4-0.6 mg protein/sample) is incubated with 100 ⁇ l (1.5-1.8 nM) 3 H-8-hydroxy-2-(di-n-propylamino)tetraline in a final volume of 2 ml of buffer for 10 minutes at 37° C.
• 3 ml of cold buffer A are added to each tube, and the contents rapidly filtered through Whatman GF/B glass filters.
• the filters are then rapidly washed 2 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail.
• the vials are then counted in a Packard 460 CD scintillation counter.
• Specific binding is calculated for each of the treatment protocols and is defined as total binding less binding in the presence of excess unlabeled serotonin (1 ⁇ M). Specific binding obtained in vehicle-treated rats is compared to that obtained in animals receiving a single or various doses of test compound and expressed as percent of control. These results are then plotted as logit % binding vs. log concentration of test drug. Linear regression analysis then yields a straight line with 95% confidence limits from which an IC5Q can be inversely predicted. K[ (inhibition constant) for the test drug is then calculated by the formula:
• test compound also permits the calculation of an ID50 value, i.e. an inhibitory dose that displaces 50% of the specific binding ex vivo.
• ID50 value i.e. an inhibitory dose that displaces 50% of the specific binding ex vivo.
• buspirone (30 mg/kg) displaced 46% of specific 3H-8-OH-DPAT binding from hippocampal membranes.
• the compounds of the invention gave the following results.
• the compounds of the invention are also studied for their ability to inhibit limbic D-2 dopamine receptor binding.
• This in vitro assay measures the ability of the compounds tested to bind to the dopamine receptor sites. Those compounds which exhibit a weak binding effect have a low liability to display potential extrapyramidal side effects.
• Limbic brain tissue (nucleus accumbens, septal area, olfactory tubercle) is dissected and homogenized on ice in 9 volumes of buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM C1, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% L-ascorbic acid, 10 ⁇ M pargyline HC1, pH 7.1) using a Polytron homogenizer at setting 5 for three 15-sec bursts. The homogenate is then diluted 4-fold with buffer and centrifuged at 30,000 x g for 20 minutes, and the supernatant is discarded.
• buffer 50 mM Tris-HCl, 120 mM NaCl, 5 mM C1, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% L-ascorbic acid, 10 ⁇ M pargyline HC1, pH 7.1
• the pellet is resuspended in the same volume of buffer and recentrifuged as before, again discarding the supernatant. This pellet is then resuspended in the same volume of buffer used in the homogenization, and the protein content of this preparation is assayed by the Lowry method.
• the homogenate is stored frozen at -70° C until use.
• the filters are then rapidly washed 3 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail.
• the vials are then counted in a Packard 460 CD scintillation counter.
• Specific binding is defined as total binding less binding in the presence of 1 ⁇ M (+)butaclamol. Binding in the presence of various concentra- tions of test drug is expressed as a percent of specific binding when no drug is present. These results are then plotted as logit % binding vs. log concentra ⁇ tion of test drug. " Linear regression analysis then yields a straight line with 95% confidence limits from which an IC50 can be inversely predicted. Kj (inhibition constant) for the test drug is then calculated by the formula:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22384843

Family Applications (1)

Country Status (3)

Families Citing this family (4)

Family Cites Families (13)

• 1988
  • 1988-11-10 WO PCT/US1988/003924 patent/WO1989004311A1/en not_active Ceased
  • 1988-11-10 EP EP19880910347 patent/EP0348460A4/en not_active Withdrawn
  • 1988-11-10 AU AU27172/88A patent/AU2717288A/en not_active Abandoned

Also Published As

Similar Documents

Legal Events